Opinion|Videos|September 23, 2024
Contemporary Guidelines for CRM Conditions
Key Takeaways
- Professional organizations have developed guidelines to manage the interconnectivity of CRM conditions, reflecting advancements in understanding cardiovascular, renal, and metabolic health.
- Recent updates in guidelines include the integration of novel therapeutic agents and personalized treatment strategies, enhancing evidence-based practices.
Key opinion leaders review current guidelines for cardiometabolic conditions, emphasizing recent advancements in the field.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do guidelines from professional organizations, including ACC, AHA, ADA, KDIGO, ACE, and DCRMi, address the management and interconnectivity of CRM conditions?
- How have these guidelines evolved in recent years? What are the notable guideline updates in recent years?
- What impact have these guidelines had on the treatment outcomes of patients with CRM conditions?
- What gaps are there in these guidelines regarding the management of CRM conditions?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
4
Value-Based Care Interventions and Management of CKD Progression
5
